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Abstract
Background: Co-inheritance of a-thalassemia was reported to be associated with a delayed age of disease onset among
Cameroonian Sickle Cell Anemia (SCA) patients. The present study aimed to explore the correlation between a-thalassemia,
hematological indices, and clinical events in these patients.
Methods and Findings: We studied 161 Cameroonian SCA patients and 103 controls (59.1% HbAA) with median ages of
17.5 and 23 years. RFLP-PCR was used to confirm SCA genotype and to describe haplotypes in the HBB-like genes cluster.
Multiplex Gap-PCR was performed to investigate the 3.7 kb a-globin gene deletions. SNaPshot PCR, capillary electrophoresis
and cycle sequencing were used for the genotyping of 10 SNPs in BCL11A, HMIP1/2, OR51B5/6 and HBG loci, known to
influence HbF levels. Generalised linear regression models adjusted for age, sex and SNPs genotypes was used to investigate
effects of a-thalassemia on clinical and hematological indices. The median rate of vaso-occlusive painful crisis and
hospitalisations was two and one per year, respectively. Stroke was reported in eight cases (7.4%). Benin haplotype was the
most prevalent (66.3%; n = 208 chromosomes). Among patients, 37.3% (n = 60) had at least one 3.7 kb deletion, compared
to 10.9% (n = 6) among HbAA controls (p,0.001). Among patients, the median RBC count increased with the number of
3.7 kb deletions [2.6, 3.0 and 3.4 million/dl, with no, one and two deletions (p = 0.01)]. The median MCV decreased with the
number of 3.7 kb deletion [86, 80, and 68fl, with no, one and two deletions (p,0.0001)], as well as median WBC counts
[13.2, 10.5 and 9.86109/L (p,0.0001. The co-inheritance of a-thalassemia was associated with lower consultations rate
(p = 0.038).
Conclusion: The co-inheritance of a-thalassemia and SCA is associated with improved hematological indices, and lower
consultations rate in this group of patients. This could possibly improve their survival and explain the higher proportion of
a-thalassemia among patients than controls.
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Introduction
Sickle cell disease is a life-long genetic disease that begins in
childhood, affecting the structure of erythrocytes. Typically, a
single DNA mutation within the beta globin gene leads to a
glutamic acid to valine substitution, changing normal hemoglobin
(HbA) into abnormal sickle hemoglobin (HbS). In deoxygenating
or dehydrating conditions, HbS polymerizes within the erythro-
cytes, leading to intracellular tactoids that deform the red blood
cells into the characteristic sickled shape, inducing microvascular
obstruction, abnormal adhesion of leukocytes and platelets,
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inflammation and hypercoagulation. Individuals with SCA suffer a
wide range of complications: increased susceptibility to infections,
chronic hemolytic anemia; recurrent periodic acute vaso-occlusive
events, and chronic damage affecting almost every organ system
[1].
The allele frequency of the HbAS matches the regions of highest
malaria endemicity, supporting the hypothesis that HbAS confers
protection against severe malaria [2]. An estimated 305 800
neonates are affected annually with nearly two-thirds of these
occurring in Africa. Sickle Cell Anemia (SCA; HbSS form) is by
far the most prevalent and severe form of the disease [3]. The lack
of effective early detection and treatment initiatives has resulted in
a high SCA-related death rate in some African countries [4].
Cameroon is a country of about 20 million inhabitants and has a
population growth of 3% per annum. The country has a high
carrier frequency of SCA, ranging from 8 to 34% [5]. Although
Cameroon has developed a national control programme for SCA,
there is not yet provision of neonatal screening, nor is there a
specialized center for lifelong medical care and surveillance for this
major cause of morbidity and mortality in this country [6]. There
is no universal medical insurance coverage in Cameroon, and care
of SCA patients is heavily dependent on families. Poverty in
Cameroon affects more than 50% of the rural population and up
to 30% of the urban population [7], contributing to a high burden
of SCA on parents [6]. Cameroonian SCA patients can present
with exceptionally severe phenotypes, as illustrated by a high rate
of stroke [8] and severely impaired neurocognitive functions [9].
Although SCA is genetically characterised by a single point
mutation, there are various genetic modulators that affect the
phenotype of this disease, and patients can manifest with varying
degrees of clinical severity [10]. Increased levels of fetal
hemoglobin (HbF), and genetic loci associated with this trait,
have been shown to influence the clinical severity of SCA [11];
research has recently replicated these findings in Cameroonian
SCA patients [12]. In addition, co-inheritance of a-thalassemia
has been associated with a milder phenotype in SCA patients, e.g.
lower stoke rate [13], but could also result in the increase of vaso-
occusive painful episodes [14].
There is a scarcity of data on the co-inheritance of a-
thalassemia and SCA in Africa [15;16,17], and surprisingly, there
have been no reports on the impact of a-thalassemia on the clinical
phenotype of SCA patients in Africa. SCA patients that live on the
African continent, unlike e.g. African American patients, are
exposed to malaria that can potentially alter the frequency of a-
thalassemia [2], therefore the pattern of co-inheritance with SCA.
Recently, we reported that co-inheritance of 3.7 kb a-globin gene
deletion was associated with a delayed age at diagnosis and
possibly improved survival of Cameroonian patients [15]. The
present study aimed to explore the correlation between 3.7 kb a-
globin gene deletion and hematological indices among patients
and controls, and its relation to clinical severity among patients.
Materials and Methods
Ethical approval
The study was performed in accordance with guidelines of the
Helsinki Declaration (Brazil, 2013). Ethical approval was given by
the National Ethical Committee Ministry of Public Health,
Republic of Cameroon (No 033/CNE/DNM/07); and the
University of Cape Town, Faculty of Health Sciences Human
Research Ethics Committee (HREC REF. 132/2010). Written
and signed informed consent was obtained from participants who
were 18 years or older, and for the children, consent was obtained
from parents/guardians with an assent from the children
participants older than seven years.
Patients and clinical events
The study was conducted at the Yaoundé Central Hospital, and
Douala Laquintinie Hospital in Cameroon. Socio-demographic
and clinical data were collected by means of a structured
questionnaire. Parents/guardians as well as adult SCA patients
were interviewed; patients’ medical records were reviewed, to
delineate their clinical features over the past three years. In the
seminal Cooperative Study in the USA, three adverse events
served as proxies for severe sickle cell disease: 1) the rate of vaso-
occlusive painful crisis (VOC), 2) the occurrence of stroke and 3)
the rate of acute chest syndrome [18]. In Cameroon, it was
virtually impossible to assess the rates of acute chest syndrome
episodes retrospectively, because of the inherent difficulties in
diagnosing acute chest syndromes in the settings and poor medical
records. Consequently, acute chest syndromes were not considered
in our evaluation. Nevertheless, we included the number of
consultations and hospitalisations, as additional proxies of clinical
severity. In addition, blood transfusions and any administration of
hydroxyurea were recorded. VOC events were defined as episodes
that could not be attributed to causes other than SCA and
required hospital visits and treatment with pain killers. Anthro-
pometric variables [Body Mass Index (BMI), and Blood Pressures
(BP)] were measured upon arrival at the hospital.
The sampling was not restricted to hospital-based patients to
avoid overrepresentation of the most severe phenotypes. To fulfil
this goal, two SCA patient associations in Cameroon were
engaged for collaboration, and additional patients were recruited
during their monthly meetings. No incentive was provided for
participation in the study. Only patients who had not received a
blood transfusion or hospitalisation in the past 6 weeks were
included, with no patient receiving hydroxyurea treatment.
The control group were randomly selected individuals (HbAS
and HbAA) who were apparently healthy blood donors, and who
volunteered their participation in the study. The following
information was collected from control participants: a complete
hematological profile (full hematological indices and Hb electro-
phoresis results), and minimal socio-demographic data (age and
gender).
Hematological phenotypes
Hemoglobin electrophoresis and complete routine blood count
of the SCA-affected patients were conducted upon arrival at the
hospital. Two methods of HbF detection were employed in this
study: 1) the Alkali Denaturation Test (ADT) initially, and 2) High
Performance Liquid Chromatography (HPLC), when it became
available (BIORAD D-10, USA). HbF detection was performed at
the hematological laboratory of the Centre Pasteur in Yaoundé.
Measurements done in patients ,5 years old were excluded from
the analysis because HbF levels are not yet stable at this early age.
ADT was used to measure HbF levels in 28% (n = 39) of controls
and 72% (n = 100) of SCD patients. These two techniques
displayed differences in median values (p = 0.001) with ADT
yielding a median value of 11.2% compared to 6.6% for the
HPLC method.
Genotypes
DNA was extracted from peripheral blood of both patients and
controls, following instructions accompanying the commercial
DNA isolation kit [Puregene blood kit (Qiagen, USA)], in the
molecular diagnostic laboratory, Gyneco-Obstetric and Paediatric
Hospital, Yaounde, Cameroon. Genotypic analyses were per-
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formed in the Division of Human Genetics, Faculty of Health
Sciences, University of Cape Town.
Molecular diagnostic testing for SCA (HbSS). PCR
primers were designed to optimally amplify a 770 bp segment of
the b-globin gene: PCR was carried out in a thermocycler
(BIORAD, USA) and analysis for the sickle-cell mutation involved
restriction enzyme analysis of the PCR product, using the
restriction endonuclease Dde I (GIBCO-BRL, USA). Only
patients identified to be HbSS type were included in the analysis,
according to a reported method [19].
Haplotyping of the b-globin gene cluster. Five restriction
fragment length polymorphism (RFLP) regions in the b-globin
genes cluster were amplified using published primers and methods
to analyse the XmnI (5’Gc), HindIII (Gc), HindIII (Ac), HincII
(3’’Yb), and HinfI (5’b) restriction fragments. RFLP sites and the
fragments were visualised by agarose gel electrophoresis and b-
globin gene haplotypes were defined by the study of the
combination of the restriction sites [20].
Detection of 3.7 kb a-globin gene deletions. Alpha-
thalassemia is caused most frequently by deletions involving one
or both a-globin genes [21]. The 3.7 kb a-globin gene deletions is
the most prevalent in sub-Saharan Africans, among whom point
mutations has been seldom reported in a-globin gene [22]. Alpha-
globin gene deletions were screened by multiplex gap-PCR
following the method reported previously [23], with a few
modifications: only five primers were required for the detection
of 3.7 kb and 4.2 kb deletions. The Expand Long Template PCR
system was utilised with buffer 3 (Roche, Mannheim, Germany),
and DMSO (1.5%) (Thermo Scientific, California, USA) was
added.
SNPs genotyping in the HMIP, BCL11A, HBG XmnI-158
and OR51B5/6 loci. In a separate study, we reported that
sequence variants at BCL11A and HBS1L-MYB loci influenced
HbF levels. In addition to BCL11A rs4671393 SNPs that was
associated with wider range of hematological indices, indepen-
dently of HbF levels and two SNPs in HBS1L-MYB that were
associated with the number of hospitalisation [12]. In this paper
we also investigated the effects of a-thalassemia on clinical and
hematological indices, in relation to these variants. For this
purpose, ten regions containing specific SNPs were amplified: viz,
for the BCL11A locus, SNPs rs11886868 and rs4671393; for the
HMIP1/2 loci: SNPs rs28384513, rs9376090, rs9399137,
rs9389269; rs9402686 and rs9494142; for the OR51B5/6 loci:
SNP rs5006884, for HBG loci, SNP rs7482144. PCR was
performed to determine genotypes using SNaPshot multiplex
ready reaction mix (Applied Biosystems, California, USA);
followed by capillary electrophoresis (Applied Biosystems Califor-
nia, USA) and cycle sequencing (Gene Amp PCR system 9700)
were used for the genotyping of the 10 selected SNPs, as previously
reported. We previously reported the details of these experiments
[12].
Statistical analysis
A Hardy-Weinberg Equilibrium (HWE) test was performed on
the genotype results of 3.7 kb a-globin gene deletions and the 10
selected SNPs. Observed 3.7 kb a-globin gene deletion allele
frequencies in controls were consistent with HWE (x2 = 2.37;
p = 0.12), equally to SCA patients (x2 = 1.69; p = 0.19). Two SNPs
were dropped because of significant violation of HWE (rs1188686
in BCL11A; HWE p-value = 0.00030; and rs9389269 in the
HBS1L-MYB locus; HWE P-value: 0.002876). And two others
SNPs were monomorphic (rs9376090 in the HBS1L-MYB locus, all
the patients were T/T homozygous; and rs7482144 in HBG loci,
all the patients were G/G homozygous).
Descriptive statistics was performed for all quantitative data
using SPSS (IBM, USA version 21.0). The distribution of variables
of interest was assessed by the Shapiro-Wilk test and informed the
use of non-parametric tests to compare groups of participants
(Mann-Whitney U test, median test or the Kruskal-Wallis).
Additive model per copy of the a-globin gene deletions were
performed, as well as multinomial, or linear logistic regression
analysis incorporating SCA genotype, a-thalassemia genotype,
age, gender, or clinical events. In addition, to correct for the
skewness of the HbF distribution, we log10-transformed and
normalized the data to obtain the quantitative trait used in the
association analysis (after correcting for age, gender, and
electrophoresis technique). The effects of a-thalassemia on key
clinical and hematological indices were investigated in generalised
linear regression models, adjusted for age, sex and six SNPs
genotypes (always assuming log-additive genetic effects) using the
R statistical package version 3.0.3 [06.03.2014], The R Founda-
tion for statistical computing, Vienna, Austria). Significance was
set at the 0.05 level.
Results
Socio-demographic data
All 161 SCA patients and 103 controls (59.1% HbAA; n = 55)
lived in the urban and peri-urban area of Yaoundé and Douala,
the two biggest cities in Cameroon; 51% (n = 76) of patients and
67.8% (n = 59) of controls were female, with a significantly higher
proportion of females among controls (p = 0.043).
Patients were relatively younger than controls (p,0.001) and
the median age of SCA patients was 17.5 years (25th percen-
tile = 11 years; 75th percentile = 24 years). The median age of
HbAS controls was 24 years (25th percentile = 17.5 years; 75th
percentile = 26 years) and that of HbAA controls was 26.5 years
(25th percentile = 23.2 years; 75th percentile = 30 years).
Anthropometric variables and clinical events in SCA
patients
The patients displayed median systolic and diastolic blood
pressure of 108 mmHg (25th percentile = 101 mmHg; 75th
percentile = 116 mmHg) and 58 mmHg (25th percentile = 53;
75th percentile = 62.2). The median BMI was 18.2 kg/m2 (25th
percentile = 15.7 kg/m2; 75th percentile = 21.4 kg/m2).
After the review and validation of clinical data/events from
parents/patients’ interviews and medical records, a maximum of
121 patients had data that were suitable for the analysis (Table 1).
The median rate of VOC was 2 per year (25th percentile = 1 per
year; 75th percentile = 4 per year) and the median rate of
hospitalisations was 1 per year (25th percentile = 0 per year; 75th
percentile = 2 per year) (Table 1). High rate of VOC (.3 per year
among 43% patients) and relatively high rates of overt strokes (8
cases; 7.4%) were indicative of severe phenotypes among patients.
Linear regression analysis incorporating the age of patient and
gender does not revealed any differences in rate of VOC and
hospitalisations. Though males tended to have a higher rate of
VOC (Likelihood Ratio p = 0.09).
Hematological indices among SCA patients and controls
Hematological indices among patients and controls are sum-
marised in Table 2, reporting in patients, a normocytic
normochromic anemia, with higher lymphocyte and platelet
counts, and also a higher HbF and HbA2 levels than those of
controls.
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Haplotypes in the b-globin-like genes cluster among SCA
patients
HBB gene haplotype data revealed the following frequencies,
per number of chromosomes: Benin (66.3%; n = 208), Cameroon
(21%; n = 66), atypical (11.1%; n = 35), Bantu (1.3%; n = 4), and
Arab/Saudi-Indian (0.3%; n = 1). No Senegal haplotype was
found. In combination, the Benin/Benin (42.2%; n = 71), Benin/
Cameroon (26.8%; n = 42), Benin/atypical (14%; n = 22) and
Cameroon/Cameroon (5.1%; n = 8) haplotypes were the most
prevalent. There were no significant differences, when studying
the association among the main groups of haplotype combinations
and the hematological indices, clinical events or HbF levels (data
not shown).
Prevalence and allele frequency of 3.7 kb a-globin gene
deletion among patients and controls
Among controls (HbAS and HbAA), 20.4% (n = 19) had at least
one 3.7 kb a-globin gene deletion, compared to 37.3% (n = 60)
among patients (p = 0.007). HbAS controls had more 3.7 kb a-
globin gene deletions than HbAA controls (p = 0.02) and the
proportion of HbAS controls with one or two 3.7 kb a-globin gene
deletions were 34.2% (n = 13); the proportion of HbAA controls
with at least one 3.7 kb a-globin gene deletion was 10.9% (n = 6)
(Fig 1A). Similarly, allele frequencies of the 3.7 kb a-globin gene
deletions were 11.8% and 22% in controls (HbAA and HbAS) and
patients (p = 0.006), respectively. Allele frequency HbAS controls
of was 19.7% (n = 15) and that of Hb AA controls was 6.4% (n = 7)
(Fig. 1B).
Multinomial logistic regressions analysis incorporating SCA
genotype, a-thalassemia genotype, age and gender indicated that,
the differential frequency of 3.7 kb a-globin gene deletions among
patients and controls was mostly driven by the genotype of HbAA
individuals. HbAA individuals were about 4 times less likely to
have a single 3.7 kb a-globin gene deletion [exponentiation of the
b coefficient (95% Confidence Interval) = 4.02 (1.45–11.13)] and 5
less likely to have a double 3.7 kb a-globin gene deletion than
HbSS patients [exponentiation of the b coefficient (95% Confi-
dence Interval) = 5.42 (0.65–44.79)].
In addition, multinomial logistic regression analysis showed that
the allele frequencies among patients as compared to controls
tended, non-significantly, to be influenced by gender and to a
lesser extent by age. Considering sickle genotype, 3.7 kb a-globin
gene genotype and gender, multinomial analysis indicated that,
being male increased the likelihood of having the 3.7 kb a-globin
gene deletion (Likelihood Ratio p = 0.013).
Co-inheritance of SCA and a-thalassemia: hematological
indices and clinical events
After univariate analysis, the co-inheritance of 3.7 kb a-globin
gene deletion and SCA was significantly associated with a lower
MCV and higher RBC, WBC, monocyte and lymphocyte counts
(Table 3) and no significant differences were observed across a-
thalassemia genotypes, when comparing anthropometric variables
and clinical events (Table 1).
Effects of a-thalassemia on key clinical and hematological
indices in generalised linear regression models, adjusted for age,
sex and five SNPs that influence HbF levels are summarised on
Table 4. The co-inheritance of alpha-thalassemia was associated
with lower consultation rate (p = 0.038). The effects of the co-
inheritance of a-thalassemia on RBC count, MCV and lympho-
cytes count were still observed (Table 4). Two SNPs were
associated with specific hematological indices: BCL11A
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Table 4); HMIP rs9399137 was significantly associated with lower
lymphocyte count (estimate = 22.09816; standard devia-
tion = 1.02912; p = 0.044) and borderline associated with lower
platelets count (estimate = 276.72; standard deviation = 43.16;
p = 0.078). In addition, being female was associates with higher
MCV (estimate = 3.88, standard deviation = 1.73; p = 0.02), higher
HbA2 (estimate = 1.02; standard deviation = 0.48; p = 0.035) and
higher HbF level (estimate = 3.82; standard deviation = 1.44;
p = 0.009).
Discussion
A high prevalence of the 3.7 kb a-globin gene deletion has also
been reported among SCA patients in Brazil (29%) [24], in India
(32%) [25], in the UK among African Britons (34%) [26], in
Figure 1. Co-inheritance of a-thalassemia among patients and controls. Panel A displays a much higher prevalence of 3.7 kb a-globin gene
deletions among patients compared to unaffected controls [HbAA and HbSS combined (p = 0.003)]. This difference was mostly driven by a much
lower proportion of 3.7 kb a-globin gene deletions among HbAA controls. Panel B displays the allele frequencies of the 3.7 kb a-globin gene
deletions among patient and control. The frequencies were 22% among patients and 11.8% among controls (HbAS and HbAA combined) (p = 0.006).
HbAS controls had more 3.7 kb a-globin gene deletions than HbAA controls (p = 0.02).
doi:10.1371/journal.pone.0100516.g001
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Guadeloupe (36%) [27], in Saudi Arabia (40%) [28], in the USA
among African Americans (41%) [29], in Oman (43%) [30], in
France among Africans (48%) [31], and in Tanzania (58%) [16].
However, none of these studies compared the prevalence of 3.7 kb
a-globin gene deletion to unaffected controls from the same
setting. By doing this, the present study has provided a unique
contribution toward consolidating the hypothesis of a possible
positive effect of the 3.7 kb a-globin gene deletion on survival of
SCA patients [15]. A decade ago in Congo, researchers reported a
less stringent difference with 67.2% SCA patients who had co-
inherited the 3.7 kb a-globin gene deletion, as compared to 54.8%
of HbAA adults [17]. In Yemen, a similar trend was reported with
34.6% of SCA patients carrying the 3.7 kb a-globin gene deletion,
compared to 26.3% in the HbAA group [32]. To support our
findings, the prevalence of controls individual (HbAS and HbAA)
who have at least one 3.7 kb a-globin gene deletion in the present
study (20.4%) is comparable to that reported previously in many
other settings across Africa. The prevalence of 3.7 kb a-globin
gene deletion was: 15.8% in Kenya [33], 15.1% in Rwanda [34],
20.8% in Guinea (West Africa) [35], and 10%–25% in high-
altitude villages in Northern Tanzania [36]. Nevertheless,
comparison across populations from different ethnicities and
geographical location needs some caution, as the advantageous
effect of a-thalassemia is clearly associated with altitude, age of
individuals and endemicity of malaria [36]. Individually, HbS and
a-thalassemia, are protective against severe Plasmodium falciparum
malaria, but, there is a possible negative epistasis between a-
thalassaemia and sickle cell trait which can modulate the inter
population variation [2]. Thus, the significance of a much higher
prevalence of 3.7 kb a-globin gene deletion among HbAS than
HbAA controls reported will require further investigations in
relation to malaria protection.
Noticeably, in a seminal work in the USA, authors reported
three decade ago that, in the first ten years of life among HbSS
individuals, the prevalence of 3.7 kb a-globin gene deletions was
comparable to that in the general African American population
(17%), while after 20 years of age, the prevalence increased to 49%
[37]. Equally, the prevalence of the 3.7 kb a-globin gene deletion
increased with age in Cuban SCA patients [38]. In addition to the
higher proportion of 3.7 kb a-globin gene deletions among
patients, we reported that the co-inheritance of 3.7 kb a-globin
gene deletions delayed the onset of clinical manifestations [15].
These data, in addition to previous report, are implying that co-
inheritance of a-thalassemia could be associated with longer
survival of SCA patients. Nevertheless, the delayed age of first
symptoms may not necessarily be related to lifetime milder clinical
expression. Interestingly, after multivariate analysis in the present
study, the co-inheritance of a-thalassemia was shown to be
associated with lower consultation rate. But, in the present first
attempt in both Cameroon and Africa, we did not find any
significant influence of the co-inheritance of the 3.7 kb a-globin
gene deletion and other clinical events in SCA (Table 1). This is
not necessarily unexpected, due to the small sample size and the
challenge to define a SCA severity scoring that could be
universally used [39]. Specifically, the potential deleterious effect
of a-thalassemia on the number of painful episodes reported
previously [14,27], could be difficult to validate in a context, such
as Cameroon, where free medical services for patient is
unavailable. Pain tolerance and socio-economic factors could
have influenced the number of hospital visits and biased our
evaluation of clinical events. If designed appropriately, future
studies in Africa could explore the potential beneficial effect of the
co-inheritance of a-thalassemia and SCA, on specific phenotype
such as lower hemolysis [40], lower frequency of gallstones [41],
lower albuminuria [26,29,42] or lower risk of the occurrence of a
stroke [13,24,43]. Noticeably, the present study confirms that the
presence of 3.7 kb a-globin gene deletion improved hematological
indices and mitigates the degree of anemia in SCA patients
(Table 2).
Indeed, a-thalassemia has been shown to diminish the severity
of disease by reducing the amount of sickled RBC, increasing the
HbF level and HbA2, and decreasing the intracellular HbS level,
which results in a reduction in HbS prompted cellular destruction,
thereby improving hemolysis [44,45]. The decrease in WBC was
attributed to a drop in the hemolytic rate, the amount of sickled
red blood cells and a reduction in the inflammatory process. The
Table 4. Effects of a-thalassemia on key clinical and hematological indices, in generalised linear regression models, adjusted for
age, sex and five SNPs* that influence HbF level.
Outcomes Unit of measurement
Single deletion vs. No





Consultations Day/year 21.32 (0.63) 0.038 21.31 (1.06) 0.221 110
Hospitalisation Day/year 20.17 (0.34) 0.608 20.37 (0.57) 0.514 104
Vaso-occlusive crisis Number/year 20.57 (0.50) 0.253 21.49 (0.84) 0.079 121
RBC count million cells/ml 0.37 (0.16) 0.021 1.03 (0.27) 0.0002 149
Hemoglobin g/dl 0.58 (0.37) 0.120 0.72 (0.63) 0.25 150
HbA2 (%) 0.23 (0.52) 0.656 0.04 (0.87) 0.956 143
HbF (%) 21.55 (1.57) 0.327 0.97 (2.64) 0.715 147
MCV fl 25.72 (1.89) 0.003 218.18 (3.19) ,0.0001 150
WBC count X109/L 23.43 (1.04) 0.001 24.31 (1.75) 0.015 150
Lymphocytes count X109/L 22.15 (0.655) 0.001 22.41 (1.102) 0.030 130
Monocytes count X109/L 20.51 (0.20) 0.01 20.67 (0.34) 0.05 130
Platelets count X 109/L 24.80 (27.49) 0.86 245.42 (46.23) 0.32 149
*HbF related SNPs are: BCL11A rs4671393, HBS1L-MYB rs28384513, HBS1L-MYB rs9399137, HBS1L-MYB rs9402686, HBS1L-MYB rs9494142 and OR51B5/6 rs5006884.
doi:10.1371/journal.pone.0100516.t004
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extent of the protective effect was also shown to be in accordance
with the amount of a-globin genes deleted [24]. The improved
hematological indices could be the major factor that contributes to
ameliorate the general well-being and possibly survival of SCA
patients, and ultimately explain a much higher prevalence of
3.7 kb a-globin gene deletion among patients, than HbAA
controls. Nevertheless, in the present study, the results of the
generalised linear regression models seem to indicate that others
genomic factors as well as demographic factors could also affect
the hematological indices (Table 4).
Limitations
The first limitation of the study is the relatively small sample
sizes of patients and controls that were not age gender or ethnically
matched. Another methodological limitation is the limited use of
the gold standard, i.e. HPLC method to measure HbF, because
the ADT method is less precise [46], and this could have affected
the association of haplotypes, to HbF levels and clinical events.
Nevertheless, in a different study, we disaggregated SCA patients
sample, based on the HbF assessment technique (ADT vs HPLC),
and found that the significant associations with HbF levels,
examined independently, were present in both sub-groups studied
using the different assay methods, in rs4671393 (BCL11A),
rs28384513 (HMIP 1) and rs9494142 (HMIP 2) [12]. The self-
reported nature of clinical variables such as VOC episodes limits
the interpretation of the results, as pain tolerance and the financial
status could have been modifying factors for hospital attendances.
Practical implications and perspectives
The possibility that a-thalassemia could have a strong effect on
survival of SCA patients, offers the prospect of profiling patients
from birth and addressing a closer follow up. To define a global
severity scale for the purpose of genomic studies of SCA is
challenging; however, some preliminary data are encouraging.
Indeed, in a recent study in Cameroon, two SNPs in HBS1L-MYB
that influence HbF level were also associated with the number of
hospitalisations and in the present study the co-inheritance of a-
thalassemia was associated with lower consultation rate. If
confirmed, these data could add to the evidence of the clinical
effects that are associated with these variants, and a clue on how to
measure them. It will be interesting in future on a much larger
sample size, to study the concurrent effects of the various genomic
loci that influence HbF level, a-thalassemia, socio-demographic
and environmental factors such as bacteraemia and malaria, on
the survival of patients, in both urban and rural settings.
Despite the fact that more than 70% of SCA sufferers live in
Africa, most advances in the molecular understanding and
management of SCA have been based on research conducted in
the USA or Europe. In the context of Africa, SCA could be
consider a neglected tropical disease [47]; thus, the capacity-
building dimension that this study provides is worth to be
underlined, as it was completely performed on the African
continent and could create further research opportunities.
Conclusion
The study confirmed the co-inheritance of a-thalassemia with
improved hematological indices and lower consultations rate,
which could contribute ameliorate the general well-being and
possibly the survival of patients; and ultimately explain the higher
proportion of 3.7 kb a-globin gene deletion among SCA patients
than controls, specifically HbAA individuals.
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